The promise of mRNA technology seemed boundless after the success of the coronavirus vaccines, but Robert F. Kennedy Jr. has ...

The safety of approved mRNA vaccines is well-established and, as with other vaccines, continues to be monitored by multiple ...

BioNTech is acquiring CureVac in a deal that brings messenger RNA manufacturing capability and cancer immunotherapy ...

The Trump administration is eroding national pandemic flu defenses as it guts health agencies, cuts research and health ...

Click in for more news from The Hill{beacon} Health Care Health Care   The Big Story Trump administration vs. mRNA vaccines ...

Moderna (MRNA) ended the recent trading session at $26.68, demonstrating a -2.45% change from the preceding day's closing price. The stock's change was less than the S&P 500's daily loss of 1.13%. At ...

WASHINGTON — mRNA, a Nobel-winning technology harnessed by Trump officials to create Covid shots in record time, is becoming ...

BioNTech is buying fellow German mRNA vaccine developer CureVac in an all-stock transaction that values the acquired biotech ...

The acquisition boosts BioNTech’s mRNA design and manufacturing capabilities, accelerating development of next-gen cancer ...

BioNTech has agreed to buy another specialist in mRNA-based vaccines and therapeutics, fellow German biotech CureVac, in an ...

Cuts in NIH grants and the threat of more are discouraging investment and may drive trials out of the United States.

A new type of mRNA vaccine is more adaptable to mutating viruses like SARS-CoV-2 and the bird flu, according to research from ...